Clinical trial NCT02937558: CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Official title: A Phase 2 Proof-of-Concept Study of CSI-Glucagon™ (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Congenital Hyperinsulinism
Keywords: hypoglycemia
Lead sponsor: Xeris Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2016-10-18
Enrollment: 5
Sex: ALL
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children \< 1 year of age with congenital hyperinsulinism.

Detailed description: This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind (DB) parallel group study with open-label follow-up designed to evaluate the efficacy of CSI-Glucagon™ for the prevention of hypoglycemia with lower IV glucose infusion rates when delivered subcutaneously to patients up to 1 year of age with congenital hyperinsulinism. CSI-Glucagon™ is expected to provide a better inpatient treatment option compared to the current standard of care.

The study will consist of three phases:

1. Baseline Phase: First is a baseline stabilization phase during which concomitant therapy with octreotide and diazoxide will be safely weaned and continuous enteric feed will be held constant to the degree possible, with the only factors varying being meal size and IV glucose infusion rate (GIR) adjusted by a set plasma glucose measurement driven algorithm.
2. Blinded, Randomized Treatment Phase: Following the stabilization phase, subjects will be randomly assigned to blinded treatment with either glucagon or placebo, which will be delivered for up to 48 hours with an OmniPod® infusion pump with the controller set to a starting basal rate for glucagon of 5 μg/kg/hr and GIR adjustments used to maintain euglycemia. After 48 hours of blinded treatment, all subjects will transition to open-label active treatment. However, if GIR reduction from baseline is \< 20% at 24 hours, subjects will be transitioned early to the open-label phase.
3. Open-label Treatment Phase: The third study period will involve use of CSI-Glucagon™ to manage blood glucose with minimal GIR for up to 28 days of cumulative exposure.

Eligibility criteria: Inclusion Criteria:

1. Diagnosed with hyperinsulinism:

   a. Biochemical; detectable insulin (i.e., ≥1 µIU/L) at time of hypoglycemia (i.e, blood glucose \<50 mg/dl), and/or suppressed free fatty acids (FFA), and/or suppressed beta-hydroxybutyrate (BOHB) and/or glycemic response to glucagon at time of hypoglycemia.
2. Absolute necessity of intravenous glucose to prevent hypoglycemia:

   1. Having failed diazoxide therapy as defined by inadequacy of 5 days maximum dose of diazoxide to eliminate the need for IV glucose, not necessarily that diazoxide has no effect.
   2. May be on diazoxide and/or octreotide, but these drugs will be weaned off prior to randomization.
   3. May be on dextrose feeds.
3. Patient may be a participant in other study protocols such as observational studies, as long as no investigational intervention has taken place within 24 hrs. prior to screening.
4. Less than 12 months of age at screening.

Exclusion Criteria:

1. History of allergy to glucagon or excipients in the CSI-Glucagon formulation.
2. Currently receiving, or less than 12 hours removed from IV glucagon treatment that resulted in a best achievable GIR \> 8 mg/(kg\*min), prior to the start of study drug.
3. Diazoxide naïve or within five days of starting diazoxide.
4. Receiving steroids at doses larger than 20 mg/m2/day (hydrocortisone equivalent).
5. Patients with sepsis.
6. Receiving alpha or beta agonists for blood pressure support.
7. Received an investigational or other study drug within 5 half-lives of drug.
8. Body weight less than or equal to 2.3 kg/5.0 lbs.
9. History of pancreatectomy and GIR \< 8 mg/(kg\*min) after weaning of all concomitant therapies.

Primary outcomes:
measure: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind)
timeFrame: Baseline to end of blinded treatment at 24 or 48 hours
Secondary outcomes:
measure: Percent Change in GIR (Double-Blind)
timeFrame: Baseline to the end of blinded treatment at 24 or 48 hours
measure: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Open-Label)
timeFrame: Baseline to the end of open-label treatment at 72 hours
measure: Percent Change in Glucose Infusion Rate (Open-Label)
timeFrame: Baseline to end of treatment at 72 hours
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA Mattel Children's Hospital
state: California
city: San Francisco
country: United States
facility: UCSF School of Medicine, Division of Pediatric Endocrinology
state: California
city: Saint Louis
country: United States
facility: Washington University, St. Louis Children's Hospital
state: Missouri
city: Fort Worth
country: United States
facility: Cook Children's Medical Center
state: Texas
city: Houston
country: United States
facility: Baylor College of Medicine, Texas Children's Hospital
state: Texas
Study officials:
References: